SCHEDULE: T. Rowe Price Adjusts Akero Therapeutics Stake

T. Rowe Price Associates, Inc. reported a 4.8% beneficial ownership in Akero Therapeutics Inc., indicating a position below the 5% threshold.

Summary

• T. Rowe Price Associates, Inc. reported beneficial ownership of 3,810,076 shares of Akero Therapeutics Inc. common stock.
• This ownership represents 4.8% of the class of securities.
• T. Rowe Price holds sole voting power over 3,731,603 shares and sole dispositive power over 3,809,859 shares.
• The filing is an Amendment No. 2 to a Schedule 13G.
• T. Rowe Price is filing as an investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E).

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of institutional ownership. While a reduction below 5% could be seen as a minor negative, the continued significant stake by a major investor provides some stability. The overall sentiment is neutral as it's a routine disclosure without performance or strategic updates from the issuer.

Positives

• A major institutional investor, T. Rowe Price, continues to hold a significant stake in Akero Therapeutics, reflecting ongoing investment interest.

Negatives

• T. Rowe Price's beneficial ownership has decreased to 4.8%, falling below the 5% threshold, which typically indicates a reduction in their overall position from a previous filing.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

NA

Stakeholder Impact

• Shareholders: The continued significant ownership by a large institutional investor like T. Rowe Price may be viewed as a sign of confidence, although the reduction below 5% could raise questions about their long-term conviction or portfolio rebalancing.

Key Dates

Keywords

Akero Therapeutics, T. Rowe Price, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Adviser